Validation of these findings with biological assays and clinical trials may corroborate the results of the present investigation proposing TRPM7 as an additional molecular mechanism and therapeutic target with TRPM3 in ME/CFS. The gene discussed is TRPM3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.